KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edwards Lifesciences (EW) Tax Provisions (2016 - 2026)

Edwards Lifesciences has reported Tax Provisions over the past 17 years, most recently at $26.2 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 41.91% year-over-year to $26.2 million; the TTM value through Dec 2025 reached $216.9 million, up 42.6%, while the annual FY2025 figure was $216.9 million, 42.6% up from the prior year.
  • Tax Provisions for Q4 2025 was $26.2 million at Edwards Lifesciences, down from $56.1 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $70.3 million in Q1 2025 and troughed at $10.9 million in Q4 2022.
  • A 5-year average of $46.5 million and a median of $50.9 million in 2021 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: plummeted 73.41% in 2022 and later surged 221.5% in 2025.
  • Year by year, Tax Provisions stood at $41.0 million in 2021, then plummeted by 73.41% to $10.9 million in 2022, then soared by 212.84% to $34.1 million in 2023, then surged by 32.26% to $45.1 million in 2024, then crashed by 41.91% to $26.2 million in 2025.
  • Business Quant data shows Tax Provisions for EW at $26.2 million in Q4 2025, $56.1 million in Q3 2025, and $64.3 million in Q2 2025.